Dr. O'Reilly on the Role of Germline Testing in Pancreatic Cancer

Video

In Partnership With:

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses germline testing in pancreatic cancer.

Germline testing should be done in all newly diagnosed patients with pancreatic cancer, recommends O’Reilly. There is about a 10% chance that a pathogenic germline mutation will be found that is significant to the patient or family, adds O’Reilly. This can lead to cascade testing family members who may be at risk for pancreatic cancer or other malignancies as well as identify a familial genetic syndrome.

With the advent of understanding the role of platinum in a group of patients with homologous repair deficiency signal, patients with germline BRCA1/2, PALB2, or other selected genes should receive platinum up front with the option of adding a PARP inhibitor, says O’Reilly.

Selective germline testing leads to testing only patients who are young, have a family history of cancer, have a personal history of cancer, or are of a specific ethnicity. By doing this, about 40% of patients with mutations are missed; this is why early germline testing is recommended for all patients upon diagnosis, concludes O’Reilly.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,